NASDAQ:GRTX

Galera Therapeutics Competitors

$8.06
-0.20 (-2.42 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.91
Now: $8.06
$8.50
50-Day Range
$8.23
MA: $10.48
$11.83
52-Week Range
$6.58
Now: $8.06
$15.00
Volume88,838 shs
Average Volume66,521 shs
Market Capitalization$201.31 million
P/E RatioN/A
Dividend YieldN/A
Beta1.89

Competitors

Galera Therapeutics (NASDAQ:GRTX) Vs. ORIC, LXRX, ESPR, KPTI, VERU, and ARDX

Should you be buying GRTX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Galera Therapeutics, including ORIC Pharmaceuticals (ORIC), Lexicon Pharmaceuticals (LXRX), Esperion Therapeutics (ESPR), Karyopharm Therapeutics (KPTI), Veru (VERU), and Ardelyx (ARDX).

Galera Therapeutics (NASDAQ:GRTX) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.

Valuation and Earnings

This table compares Galera Therapeutics and ORIC Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galera TherapeuticsN/AN/A$-51,930,000.00($16.31)-0.49
ORIC PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations and price targets for Galera Therapeutics and ORIC Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galera Therapeutics00203.00
ORIC Pharmaceuticals01602.86

Galera Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 110.92%. ORIC Pharmaceuticals has a consensus price target of $43.7143, indicating a potential upside of 102.66%. Given Galera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Galera Therapeutics is more favorable than ORIC Pharmaceuticals.

Profitability

This table compares Galera Therapeutics and ORIC Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Galera TherapeuticsN/A-151.01%-60.72%
ORIC PharmaceuticalsN/AN/AN/A

Institutional and Insider Ownership

75.4% of Galera Therapeutics shares are owned by institutional investors. Comparatively, 73.4% of ORIC Pharmaceuticals shares are owned by institutional investors. 19.3% of Galera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Galera Therapeutics beats ORIC Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Galera Therapeutics (NASDAQ:GRTX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.

Risk and Volatility

Galera Therapeutics has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500.

Institutional and Insider Ownership

75.4% of Galera Therapeutics shares are owned by institutional investors. Comparatively, 84.6% of Lexicon Pharmaceuticals shares are owned by institutional investors. 19.3% of Galera Therapeutics shares are owned by company insiders. Comparatively, 6.4% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Galera Therapeutics and Lexicon Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galera TherapeuticsN/AN/A$-51,930,000.00($16.31)-0.49
Lexicon Pharmaceuticals$322.07 million2.41$130.13 million$1.353.98

Lexicon Pharmaceuticals has higher revenue and earnings than Galera Therapeutics. Galera Therapeutics is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Galera Therapeutics and Lexicon Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galera Therapeutics00203.00
Lexicon Pharmaceuticals06202.25

Galera Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 110.92%. Lexicon Pharmaceuticals has a consensus price target of $9.40, indicating a potential upside of 75.05%. Given Galera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Galera Therapeutics is more favorable than Lexicon Pharmaceuticals.

Profitability

This table compares Galera Therapeutics and Lexicon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Galera TherapeuticsN/A-151.01%-60.72%
Lexicon Pharmaceuticals-320.44%-164.96%-31.83%

Esperion Therapeutics (NASDAQ:ESPR) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Volatility & Risk

Esperion Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500.

Institutional and Insider Ownership

75.4% of Galera Therapeutics shares are owned by institutional investors. 7.7% of Esperion Therapeutics shares are owned by insiders. Comparatively, 19.3% of Galera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Esperion Therapeutics and Galera Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Esperion Therapeutics$148.36 million5.08$-97,170,000.00($3.59)-7.51
Galera TherapeuticsN/AN/A$-51,930,000.00($16.31)-0.49

Galera Therapeutics has lower revenue, but higher earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Esperion Therapeutics and Galera Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Esperion Therapeutics24312.30
Galera Therapeutics00203.00

Esperion Therapeutics currently has a consensus target price of $50.60, indicating a potential upside of 87.76%. Galera Therapeutics has a consensus target price of $17.00, indicating a potential upside of 110.92%. Given Galera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Galera Therapeutics is more favorable than Esperion Therapeutics.

Profitability

This table compares Esperion Therapeutics and Galera Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Esperion Therapeutics-46.15%-629.88%-41.43%
Galera TherapeuticsN/A-151.01%-60.72%

Summary

Galera Therapeutics beats Esperion Therapeutics on 9 of the 14 factors compared between the two stocks.

Karyopharm Therapeutics (NASDAQ:KPTI) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Volatility & Risk

Karyopharm Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500.

Institutional and Insider Ownership

88.6% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Galera Therapeutics shares are owned by institutional investors. 13.3% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 19.3% of Galera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Karyopharm Therapeutics and Galera Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Karyopharm Therapeutics$40.89 million18.29$-199,590,000.00($3.22)-3.11
Galera TherapeuticsN/AN/A$-51,930,000.00($16.31)-0.49

Galera Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Karyopharm Therapeutics and Galera Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Karyopharm Therapeutics01802.89
Galera Therapeutics00203.00

Karyopharm Therapeutics currently has a consensus target price of $30.6250, indicating a potential upside of 205.64%. Galera Therapeutics has a consensus target price of $17.00, indicating a potential upside of 110.92%. Given Karyopharm Therapeutics' higher possible upside, research analysts clearly believe Karyopharm Therapeutics is more favorable than Galera Therapeutics.

Profitability

This table compares Karyopharm Therapeutics and Galera Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Karyopharm Therapeutics-221.23%-187.66%-56.42%
Galera TherapeuticsN/A-151.01%-60.72%

Summary

Galera Therapeutics beats Karyopharm Therapeutics on 7 of the 13 factors compared between the two stocks.

Veru (NASDAQ:VERU) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Volatility & Risk

Veru has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500.

Earnings and Valuation

This table compares Veru and Galera Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veru$42.59 million17.48$-18,970,000.00($0.11)-94.09
Galera TherapeuticsN/AN/A$-51,930,000.00($16.31)-0.49

Veru has higher revenue and earnings than Galera Therapeutics. Veru is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

23.3% of Veru shares are owned by institutional investors. Comparatively, 75.4% of Galera Therapeutics shares are owned by institutional investors. 26.1% of Veru shares are owned by insiders. Comparatively, 19.3% of Galera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Veru and Galera Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Veru-44.55%-23.72%-13.80%
Galera TherapeuticsN/A-151.01%-60.72%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Veru and Galera Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Veru00403.00
Galera Therapeutics00203.00

Veru currently has a consensus target price of $19.25, indicating a potential upside of 85.99%. Galera Therapeutics has a consensus target price of $17.00, indicating a potential upside of 110.92%. Given Galera Therapeutics' higher possible upside, analysts clearly believe Galera Therapeutics is more favorable than Veru.

Summary

Veru beats Galera Therapeutics on 7 of the 12 factors compared between the two stocks.

Ardelyx (NASDAQ:ARDX) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Volatility & Risk

Ardelyx has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.

Valuation and Earnings

This table compares Ardelyx and Galera Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ardelyx$5.28 million139.05$-94,940,000.00($1.47)-5.06
Galera TherapeuticsN/AN/A$-51,930,000.00($16.31)-0.49

Galera Therapeutics has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

85.9% of Ardelyx shares are held by institutional investors. Comparatively, 75.4% of Galera Therapeutics shares are held by institutional investors. 4.0% of Ardelyx shares are held by company insiders. Comparatively, 19.3% of Galera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Ardelyx and Galera Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ardelyx-1,063.74%-53.93%-37.42%
Galera TherapeuticsN/A-151.01%-60.72%

Analyst Ratings

This is a summary of current ratings and price targets for Ardelyx and Galera Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ardelyx00403.00
Galera Therapeutics00203.00

Ardelyx presently has a consensus target price of $14.00, indicating a potential upside of 88.17%. Galera Therapeutics has a consensus target price of $17.00, indicating a potential upside of 110.92%. Given Galera Therapeutics' higher possible upside, analysts plainly believe Galera Therapeutics is more favorable than Ardelyx.

Summary

Ardelyx beats Galera Therapeutics on 7 of the 12 factors compared between the two stocks.


Galera Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.57-7.5%$791.51 millionN/A0.00Gap Down
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.37-1.1%$775.18 million$322.07 million-5.11
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$26.95-4.7%$753.06 million$148.36 million-7.00News Coverage
Gap Down
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$10.02-1.2%$747.83 million$40.89 million-3.46
Veru logo
VERU
Veru
1.4$10.35-0.3%$744.29 million$42.59 million-36.96
Ardelyx logo
ARDX
Ardelyx
1.6$7.44-5.6%$734.18 million$5.28 million-7.37Gap Down
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$22.17-5.3%$731.97 million$252 million-2.27Gap Down
Chimerix logo
CMRX
Chimerix
1.3$8.45-2.1%$723.99 million$12.52 million-14.82News Coverage
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.82-1.8%$716.29 million$2.22 million-16.59
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.32-2.1%$714.48 million$150,000.00-4.74Gap Down
OrganiGram logo
OGI
OrganiGram
1.6$3.05-3.3%$708.43 million$64.61 million-4.49Upcoming Earnings
Analyst Upgrade
Gap Down
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$27.50-0.0%$686.58 million$19.56 million-19.78High Trading Volume
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.74-3.3%$660.12 millionN/A-2.46Gap Down
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$28.38-13.7%$655.29 million$13.80 million-13.71Insider Selling
High Trading Volume
News Coverage
Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.23-5.6%$651.22 million$143.01 million-1.19Gap Down
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$19.86-9.5%$640.68 millionN/A-10.56Gap Down
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$26.15-0.1%$635.65 million$12.69 million-12.57
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$17.62-1.3%$630.96 million$6.83 million-18.16News Coverage
Kadmon logo
KDMN
Kadmon
1.8$3.66-5.2%$628.85 million$5.09 million-6.10Analyst Upgrade
Gap Down
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$32.88-2.4%$628.47 million$9.64 million-5.36
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$14.82-3.0%$624.78 million$17.26 million-4.12Earnings Announcement
Analyst Revision
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$12.32-9.9%$598.21 millionN/A-6.32Analyst Upgrade
News Coverage
Gap Down
Evolus logo
EOLS
Evolus
1.1$13.58-2.4%$593.89 million$34.92 million-6.69Analyst Report
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$35.23-2.0%$590.00 millionN/A-16.31Gap Down
AnaptysBio logo
ANAB
AnaptysBio
1.5$20.87-6.3%$571.13 million$8 million-7.70Gap Down
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$12.04-4.1%$568.85 millionN/A-9.33Gap Down
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$15.52-3.3%$567.69 millionN/A-4.47News Coverage
Gap Up
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$17.07-4.9%$563.81 million$1.19 million-7.11Insider Buying
News Coverage
Gap Down
Inventiva logo
IVA
Inventiva
0.0$14.44-2.2%$557.76 millionN/A0.00Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.26-1.8%$554.59 million$59.29 million-21.73
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.20-5.2%$553.64 millionN/A-5.29Analyst Upgrade
Gap Down
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.4$41.56-0.9%$549.30 million$195.89 million118.75News Coverage
SIGA
SIGA Technologies
0.3$7.10-0.6%$544.91 million$26.74 million17.75
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$39.66-5.1%$535.77 million$40,000.00-1.72High Trading Volume
Gap Up
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$10.04-0.2%$535.48 millionN/A-4.03
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24-0.0%$531.75 millionN/A-3.15
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.32-0.0%$530.72 million$49.65 million-1.86News Coverage
Gap Down
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.87-4.3%$529.13 millionN/A-4.66Gap Down
89bio logo
ETNB
89bio
1.6$26.28-0.2%$524.18 millionN/A-5.20
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$21.04-5.1%$523.18 millionN/A-8.28News Coverage
Gap Down
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$5.44-10.3%$516.29 million$36.63 million-6.40Analyst Downgrade
Unusual Options Activity
Analyst Revision
News Coverage
Gap Up
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.78-0.0%$513.32 million$59.22 million43.90News Coverage
Provention Bio logo
PRVB
Provention Bio
1.6$8.00-21.6%$507 millionN/A-5.37Analyst Report
High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$11.97-0.9%$506.64 million$25 million-18.42
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$14.00-0.3%$502.28 million$58.12 million-16.28
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.72-1.2%$500.13 million$57.49 million-6.49
XBiotech logo
XBIT
XBiotech
1.0$16.95-0.4%$499.33 millionN/A1.17
AC Immune logo
ACIU
AC Immune
1.3$6.87-0.6%$494.21 million$111.75 million-7.63
Verona Pharma logo
VRNA
Verona Pharma
1.7$8.53-6.6%$494.19 millionN/A-2.59Gap Down
Altimmune logo
ALT
Altimmune
1.9$12.90-1.7%$479.24 million$5.80 million-6.48
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.